The impact of surgical excision in chest wall rhabdomyosarcoma: a report from the children's oncology group

Hayes‐Jordan, Andrea; Stoner, Julie A.; Anderson, James R.; Rodeberg, David A.; Weiner, Gene; Meyer, William H.; Hawkins, Doug; Arndt, Carola A.S.; Paidas, Charles N.

doi:10.1016/j.jpedsurg.2007.12.021

Cited by 37 publications

(18 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 In other cases, systems that involve both macroscopic and microscopic assessment of the extent of the tumor resection are used. 3,4,8,9,11,13 Nonetheless, in agreement with Dr. Barbaro, we found that both GTR as well as histological margin status played an important role in overall survival, disease-free survival, distant recurrence, and local recurrence rate in patients with NF1 with MPNSTs.…”

Section: Cancer Center and 5 Radiation Oncology Massachusetts Gen Esupporting

confidence: 88%

Editorial: Malignant nerve sheath tumors

Barbaro¹

2013

JNS

View full text Add to dashboard Cite

Dunn et al. 1 have provided a retrospective review of their institutional experience over an 18-year period during which time they treated 23 patients for malignant peripheral nerve sheath tumors in the setting of neurofibromatosis Type 1 (NF1). The authors analyzed their outcomes with respect to survival and local and distant recurrence. They were particularly interested in the role of a complete resection on survival and looked at what they term "gross-total resection [GTR]" as well as whether the surgical margins were free of tumor. They found that the surgeon's estimate of resection was significant with respect to overall survival. They provide a relatively extensive review of the literature on this topic, including adjuvant therapies, such as radiation therapy and chemotherapy. Their study does not attempt to compare the presentation or outcomes of patients with NF1 with patients without NF1.While this is not the largest series of malignant nerve sheath tumors in the literature, it provides useful data and underscores many of the relevant issues with respect to the treatment of these rare lesions. The fact that the author group included several specialty areas (neurosurgery, neurology, orthopedic surgery, medical oncology, and radiation oncology) indicates that a multidisciplinary approach has become the standard for approaching these lesions. As pointed out in the report, there is no standard therapy for these lesions that has proven effective.The authors are somewhat alone in using the term gross-total resection in relationship to surgery for this lesion. Neurosurgeons frequently use this term in describing brain tumor resections, while surgical oncologists more often use the "margin" status when referring to malignant peripheral nerve sheath tumors. 2-4 In most, but not all, studies, the presence of tumor cells on the pathological evaluation of the resected margins is negatively correlated with recurrence and survival. In this report, there were 4 cases in which tumor cells were seen by the pathologist, even though the surgeon thought that the entire tumor was resected. Although the authors describe this as occurring in 4 of their 23 patients, in actual fact, there were only 15 patients in whom the surgeon thought that a complete resection had been attained. Thus, this "error" occurred more than 25% of the time. In addition, the fact that 33% of patients who underwent "GTR" died within 5 years (43% for negative margins) indicates that there is no good indicator of surgical cure for this lesion, and that adjuvant therapy should probably be given in all cases.As discussed in the report, radiation therapy has been shown in some studies to be effective in reducing recurrence in these lesions. Recent data would suggest that a relatively high radiation dose is required for this to be true. Wong et al. 5 found that the effective dose had to be greater than 60 Gy, which is not surprising given the relative resistance to radiation for this type of lesion. In this review, the mean dose was 56 Gy, indicating that m...

show abstract

Section: Cancer Center and 5 Radiation Oncology Massachusetts Gen Esupporting

confidence: 88%

Editorial: Malignant nerve sheath tumors

Barbaro¹

2013

JNS

View full text Add to dashboard Cite

show abstract

“…There are few reports in the literature regarding treatment of CWT, given the rarity of these diseases. While few studies included CWT of all histologic origins (1–2–3–4, 7–8–9–10–11), some groups combined multicentric experiences about rare specific diseases (12) or described mono-institutional series in referred centers (13–14–15–16–17–18).…”

Section: Discussionmentioning

confidence: 99%

Surgical Approach to Primary Tumors of the Chest Wall in Children and Adolescents: 30 Years of Mono-Institutional Experience

Girelli

Luksch

Podda

et al. 2015

Tumori

View full text Add to dashboard Cite

Long-term survival is achievable for chest wall tumors in a high-volume referral center where a multimodal treatment should be set to reach the best result. As advances in medical treatment have increased survival, surgical techniques must ensure a lasting functional result. When refining the reconstruction techniques, such as the rib-like approach, it is necessary to expand the options of curative surgery for young patients.

show abstract

“…In addition, future phase III studies will incorporate standard requirements for lymph node evaluation, since regional lymph node involvement is associated with outcome in ARMS [114] and is an important site of relapse [115]. Phase III studies will include local treatment pathways that maximize local control and minimize morbidity [116][117][118][119][120].…”

Section: Key Trials To Be Pursuedmentioning

confidence: 99%

Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas

Hawkins

Spunt

Skapek

2012

Pediatric Blood & Cancer

155

158

View full text Add to dashboard Cite

In the US, approximately 850-900 children are diagnosed each year with soft tissue sarcomas (STS). Key findings from recent clinical trials include safe reduction in therapy for low risk rhabdomyosarcoma (RMS), validation of FOXO1 fusion as a prognostic factor, a modest improvement in outcome for high-risk RMS, and a biologically-designed non-cytotoxic therapy for pediatric desmoid tumor. Planned Phase 2 trials include targeted agents for VEGF/PDGF, mTOR, and IGF-1R for children with RMS and VEGF for children with non-RMS STS (NRSTS). For RMS, COG Phase 3 trials potentially will explore VEGF/mTOR inhibition or chemotherapy interval compression. For NRSTS, a COG Phase 3 trial will explore VEGF inhibition.

show abstract

The impact of surgical excision in chest wall rhabdomyosarcoma: a report from the children's oncology group

Cited by 37 publications

References 18 publications

Editorial: Malignant nerve sheath tumors

Editorial: Malignant nerve sheath tumors

Surgical Approach to Primary Tumors of the Chest Wall in Children and Adolescents: 30 Years of Mono-Institutional Experience

Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas

Contact Info

Product

Resources

About